1 |
Cassidy SB, Driscoll DJ. Prader-Willi syndrome. Eur J Hum Genet 2009;17:3-13.
DOI
|
2 |
Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocrinol Invest 2015;38:1249-1263.
DOI
|
3 |
Driscoll DJ, Miller JL, Schwartz S, Cassidy SB. Prader-Willi syndrome. 1998 Oct 6 [updated 2016 Feb 4, cited 2017 Nov 10]. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., editors. [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1330/
|
4 |
Ho AY, Dimitropoulos A. Clinical management of behavioral characteristics of Prader-Willi syndrome. Neuropsychiatr Dis Treat 2010;6:107-118.
|
5 |
Sinnema M, Boer H, Collin P, Maaskant MA, van Roozendaal KE, Schrander-Stumpel CT, et al. Psychiatric illness in a cohort of adults with Prader-Willi syndrome. Res Dev Disabil 2011;32:1729-1735.
DOI
|
6 |
Bonnot O, Cohen D, Thuilleaux D, Consoli A, Cabal S, Tauber M. Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature. Eur J Pediatr 2016;175:9-18.
|
7 |
Benjamin E, Buot-Smith T. Naltrexone and fluoxetine in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 1993;32:870-873.
DOI
|
8 |
Akca OF, Yilmaz S. Aripiprazole in the treatment of obsessive compulsive disorder and aggressive behaviors in a child with Prader Silli syndrome: a case report. J Clin Psychopharmacol 2016;36:526-528.
DOI
|
9 |
Herguner S, Mukaddes NM. Psychosis associated with fluoxetine in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 2007;46:944-945.
DOI
|
10 |
Kohn Y, Weizman A, Apter A. Aggravation of food-related behavior in an adolescent with Prader-Willi syndrome treated with fluvoxamine and fluoxetine. Int J Eat Disord 2001;30:113-117.
DOI
|
11 |
Kaufman AS, Kaufman NL. Kaufman assessment battery for children K-ABC. 8th ed. German version by Melchers P and Preuss U. Frankfurt am Main:Pearson Assessment;2009.
|
12 |
Dech B, Budow L. The use of fluoxetine in an adolescent with Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 1991;30:298-302.
DOI
|
13 |
Araki S, Ohji T, Shiota N, Dobashi K, Shimono M, Shirahata A. Successful risperidone treatment for behavioral disturbances in Prader-Willi syndrome. Pediatr Int 2010;52:e1-e3.
DOI
|
14 |
Durst R, Rubin-Jabotinsky K, Raskin S, Katz G, Zislin J. Risperidone in treating behavioural disturbances of Prader-Willi syndrome. Acta Psychiatr Scand 2000;102:461-465.
DOI
|
15 |
Yang L, Zhan GD, Ding JJ, Wang HJ, Ma D, Huang GY, et al. Psychiatric illness and intellectual disability in the Prader-Willi syndrome with different molecular defects--a meta analysis. PLoS One 2013;8:e72640.
DOI
|
16 |
Lo ST, Collin PJ, Hokken-Koelega AC. Psychiatric disorders in children with Prader-Willi syndrome-Results of a 2-year longitudinal study. Am J Med Genet A 2015;167A:983-991.
|
17 |
Briegel W. Neuropsychiatric aspects of Prader-Willi syndrome-a review. Z Kinder Jugendpsychiatr Psychother 2017;14:1-8.
|
18 |
Ventriglio A, Gentile A, Stella E, Bellomo A. Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Front Neurosci 2015;9:297.
|
19 |
Safer DJ, Calarge CA, Safer AM. Prolactin serum concentrations during aripiprazole treatment in youth. J Child Adolesc Psychopharmacol 2013;23:282-289.
DOI
|
20 |
Soni S, Whittington J, Holland AJ, Webb T, Maina EN, Boer H, et al. The phenomenology and diagnosis of psychiatric illness in people with Prader-Willi syndrome. Psychol Med 2008;38:1505-1514.
DOI
|